Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PIK3CA |
| Variant | N1044K |
| Impact List | missense |
| Protein Effect | gain of function |
| Gene Variant Descriptions | PIK3CA N1044K lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). N1044K confers a gain of function to Pik3ca protein as indicated by increased cell survival and transforming ability in cell culture (PMID: 26627007, PMID: 29533785). |
| Associated Drug Resistance | |
| Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA N1044K PIK3CA mutant PIK3CA exon21 PIK3CA N1044K |
| Transcript | NM_006218.4 |
| gDNA | chr3:g.179234289T>G |
| cDNA | c.3132T>G |
| Protein | p.N1044K |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_006713658.4 | chr3:g.179234289T>G | c.3132T>G | p.N1044K | RefSeq | GRCh38/hg38 |
| NM_006218.3 | chr3:g.179234289T>G | c.3132T>G | p.N1044K | RefSeq | GRCh38/hg38 |
| XM_006713658.5 | chr3:g.179234289T>G | c.3132T>G | p.N1044K | RefSeq | GRCh38/hg38 |
| XM_006713658 | chr3:g.179234289T>G | c.3132T>G | p.N1044K | RefSeq | GRCh38/hg38 |
| NM_006218.4 | chr3:g.179234289T>G | c.3132T>G | p.N1044K | RefSeq | GRCh38/hg38 |
| XM_011512894.2 | chr3:g.179234289T>G | c.3132T>G | p.N1044K | RefSeq | GRCh38/hg38 |
| XM_011512894 | chr3:g.179234289T>G | c.3132T>G | p.N1044K | RefSeq | GRCh38/hg38 |
| NM_006218 | chr3:g.179234289T>G | c.3132T>G | p.N1044K | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA N1044K | colorectal cancer | predicted - sensitive | Alpelisib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Piqray (alpelisib) inhibited cell proliferation in a patient-derived colorectal cancer organoid harboring PIK3CA N1044K, along with KRAS G12D, in culture (PMID: 32376656). | 32376656 |
| PIK3CA N1044K | colorectal cancer | predicted - sensitive | Taselisib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Taselisib (GDC-0032) inhibited cell proliferation in a patient-derived colorectal cancer organoid harboring PIK3CA N1044K, along with KRAS G12D, in culture (PMID: 32376656). | 32376656 |
| PIK3CA N1044K | colorectal cancer | predicted - sensitive | MK2206 | Preclinical - Patient cell culture | Actionable | In a preclinical study, MK2206 inhibited cell proliferation in a patient-derived colorectal cancer organoid harboring PIK3CA N1044K, along with KRAS G12D, in culture (PMID: 32376656). | 32376656 |